---
layout: default
title: Ublituximab
parent: 僅模型預測 (L5)
nav_order: 706
evidence_level: L5
indication_count: 10
---

# Ublituximab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ublituximab: From No Recorded Indication to Diabetic Cataract

## One-Sentence Summary

> Ublituximab is an anti-CD20 B-cell depleting monoclonal antibody; no approved original indication or mechanism-of-action detail is available in this evidence pack.
> The TxGNN model predicts a possible association with **Diabetic Cataract**, but this is supported by **0 clinical trials** and **0 publications**, and the model's own rationale flags the prediction as mechanistically implausible.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (no approved indication on record; drug class is anti-CD20 monoclonal antibody, B-cell depleting agent) |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.57% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Ublituximab in this evidence pack (flagged as a data gap requiring DrugBank verification). What is known from the accompanying rationale is that Ublituximab belongs to the anti-CD20 monoclonal antibody class, acting via depletion of CD20-positive B cells — a mechanism used therapeutically in B-cell-mediated autoimmune and haematological conditions.

Diabetic cataract, by contrast, is driven by non-immune, metabolic and oxidative pathology — chiefly hyperglycaemia-induced lens protein glycation and osmotic/oxidative stress within the lens. There is no established biological pathway linking B-cell depletion to lens crystallin damage, and no preclinical or clinical data in this pack demonstrate such a link.

The model's own annotation for this prediction states explicitly: *"no plausible mechanism — the high TxGNN score likely reflects data sparsity or indirect node-linkage noise in the knowledge graph embedding, rather than a genuine biological signal."* The same caveat applies to ranks 2–9 (other cataract subtypes) and rank 10 (diabetic retinopathy), all of which score similarly high (98.3–98.6%) with identical "no evidence" status — a pattern more consistent with an artefact affecting an entire disease cluster than with ten independent genuine signals. This prediction should be treated as **hypothesis-generating only**, not as a basis for further development at this time.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Australia Market Information

Ublituximab is not currently registered on the ARTG (Australian Register of Therapeutic Goods). No product entries, dosage forms, or approved indications are on record in Australia.

---

## Safety Considerations

As Ublituximab is not marketed in Australia, no TGA-approved Product Information is currently available. Key safety fields in this evidence pack — warnings, contraindications, and drug-drug interactions — are also flagged as data gaps (source verification pending via TFDA label PDF and DrugBank API). No safety assessment can be made until this information is obtained.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is no clinical trial or literature evidence for diabetic cataract (or any of the other 9 ranked cataract/retinopathy indications), no mechanism-of-action data on file, and the repurposing rationale itself assesses the predicted link as biologically implausible — most likely reflecting noise in the knowledge-graph embedding rather than a genuine signal. Combined with a Blocking-severity safety data gap (TFDA label unavailable) and the drug not being marketed in Australia, this candidate does not meet the threshold to advance beyond S0.

**To proceed, the following is needed:**
- Confirmed mechanism of action from DrugBank (DG002)
- TFDA/TGA-equivalent product label with warnings and contraindications (DG001, Blocking)
- Independent mechanistic rationale (preclinical or in vitro) linking anti-CD20 B-cell depletion to lens/retinal pathology, if this indication is to be pursued further
- Confirmation of whether the cluster of ten high-scoring cataract/retinopathy predictions reflects a genuine embedding signal or a systematic KG artefact, before evaluating any individual candidate in this cluster
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

